Two Hippo signaling modules orchestrate liver size and tumorigenesis

• DOI: 10.15252/embj.2022112126
• Publication Date: 2023-03-15T11:11:09Z
• Authors: Sixian Qi; Zhenxing Zhong; Yuwen Zhu; Yebin Wang; Mingyue Ma; Yu Wang; Xincheng Liu; Ruxin Jin; Zhihan Jiao; Rui Zhu; Zhao Sha; Kyvan Dang; Ying Liu; Dae‐Sik Lim; Junhao Mao; Lei Zhang; Fa‐Xing Yu
• Keywords: Hippo signaling pathway

AbstractThe Hippo pathway is a central regulator of organ size and tumorigenesis and is commonly depicted as a kinase cascade, with an increasing number of regulatory and adaptor proteins linked to its regulation over recent years. Here, we propose that two Hippo signaling modules, MST1/2–SAV1–WWC1‐3 (HPO1) and MAP4K1‐7–NF2 (HPO2), together regulate the activity of LATS1/2 kinases and YAP/TAZ transcriptional co‐activators. In mouse livers, the genetic inactivation of either HPO1 or HPO2 module results in partial activation of YAP/TAZ, bile duct hyperplasia, and hepatocellular carcinoma (HCC). On the contrary, inactivation of both HPO1 and HPO2 modules results in full activation of YAP/TAZ, rapid development of intrahepatic cholangiocarcinoma (iCCA), and early lethality. Interestingly, HPO1 has a predominant role in regulating organ size. HPO1 inactivation causes a homogenous YAP/TAZ activation and cell proliferation across the whole liver, resulting in a proportional and rapid increase in liver size. Thus, this study has reconstructed the order of the Hippo signaling network and suggests that LATS1/2 and YAP/TAZ activities are finetuned by HPO1 and HPO2 modules to cause different cell fates, organ size changes, and tumorigenesis trajectories.